A poison pill is a defensive plan a company’s board adopts to make a hostile takeover prohibitively expensive. Formally called a shareholder rights plan, it gives every existing shareholder the right to buy additional stock at a steep discount the moment an outside buyer crosses a set ownership threshold, usually between 10% and 20% of outstanding shares. The flood of cheap new shares dilutes the hostile bidder’s stake so severely that gaining majority control stops making financial sense. Pills have been the single most effective anti-takeover device available to public company boards since the mid-1980s.
How the Trigger and Dilution Work
When a board adopts a rights plan, it distributes one right per share to every existing stockholder. The rights sit dormant, attached to the common stock, doing nothing. They stay that way until someone crosses the ownership trigger the board has set, which is typically 10% to 20% of outstanding shares, though some specialized plans go as low as 4.9%.
Once the trigger is crossed, the rights spring to life. Every shareholder except the hostile bidder can exercise their rights to buy new shares at a substantial discount, typically 50% below market price. If the stock trades at $80, rights holders can pay $80 for shares worth $160, effectively a two-for-one. The hostile bidder is locked out of the discount and watches its ownership stake get diluted as millions of new cheap shares flood the market.
The math is punishing. A bidder that owns 20% of a company when the pill triggers can see that stake cut to single digits almost overnight. Regaining the same percentage would cost vastly more, which is usually enough to end the bid. Pills are rarely triggered in practice because rational bidders will not walk into the trap. The deterrent does the work.
The Main Types of Poison Pill
Not all pills are built the same. The design determines when the dilution hits and who absorbs it.
Flip-In Pills
The flip-in is the standard design and the one most companies adopt. When the ownership trigger is crossed, existing shareholders (except the bidder) can buy the target company’s own shares at a deep discount. Dilution hits the bidder immediately, before any merger or acquisition closes. This has been the default structure since the late 1980s.
Flip-Over Pills
A flip-over activates later, after the hostile bidder has already gained control and attempts a follow-up transaction like a merger or asset sale. At that stage, the target company’s shareholders gain the right to buy the acquiring company’s shares at a steep discount. The acquirer’s own shareholders then suffer the dilution, which makes the second-step deal punishingly expensive. Even a bidder that gets through the front door pays a heavy price on the way through.
Back-End Pills
A back-end pill, also called a note purchase rights plan, works differently. Instead of discounted shares, it gives shareholders the right to exchange their stock for cash or preferred securities at a price set by the board, usually above market value. That forces the acquirer to negotiate with the board rather than buying shares on the open market. The defense collapses, however, if the acquirer offers more than the back-end price, because shareholders will take the higher bid.
NOL Pills
Some pills are not about takeovers at all. A company with significant net operating loss carryforwards can lose much of its ability to use them if an “ownership change” occurs under Section 382 of the Internal Revenue Code, defined roughly as a more-than-50-percentage-point shift in ownership among major shareholders over a three-year rolling period.1Harvard Law School Forum on Corporate Governance. The Misplaced Focus of the ISS Policy on NOL Poison Pills To prevent that, NOL pills set their trigger at 4.9%, just below the 5% threshold that matters under Section 382. The mechanics mirror a traditional pill, but the goal is preserving future tax deductions rather than repelling a bidder. These plans tend to run longer than takeover pills, typically around three years, with expiration tied to exhaustion of the NOLs.
When a Pill Is Legally Valid
Poison pills derive their authority from state corporate law. Because most large public companies are incorporated in Delaware, the Delaware General Corporation Law is what matters. Section 157 authorizes any corporation to “create and issue…rights or options entitling the holders thereof to acquire from the corporation any shares of its capital stock,” with terms set by board resolution.2Delaware Code Online. Delaware Code Title 8 Chapter 1 Subchapter V The statute does not mention pills by name, but the language is broad enough to cover them.
The 1985 Delaware case Moran v. Household International confirmed that reading. Household’s board had adopted a rights plan before any specific threat materialized, and a director challenged it. The Delaware courts upheld the plan under Section 157.3Justia Law. Moran v Household Intern Inc Within a few years, hundreds of public companies had followed suit.
Having the right to adopt a pill does not mean every pill survives review. Delaware applies an enhanced scrutiny test, called the Unocal standard after the 1985 case Unocal Corp. v. Mesa Petroleum. The board has to show reasonable grounds for believing a genuine threat existed, and the defensive response has to be proportional to that threat.4Legal Information Institute. Enhanced Scrutiny Test A pill cannot be preclusive (making any offer impossible) or coercive (forcing shareholders into a decision they would not freely make).
Boards that overreach find the limits quickly. In 2021, the Delaware Court of Chancery struck down a pill adopted by The Williams Companies during the pandemic, calling it “the most extreme version of a poison pill” the court had ever seen. The board had set a 5% trigger and openly stated the plan was designed to block “all forms of stockholder activism,” without identifying any actual threat. Both prongs of Unocal failed.
Related doctrine tightens scrutiny further in specific situations. Once a board has decided to sell the company, the Revlon standard requires it to pursue the best price reasonably available for shareholders, which makes keeping a pill in place to block a higher bid hard to justify. And under the Blasius standard, any board action taken for the primary purpose of interfering with a shareholder vote requires a “compelling justification,” a heavier burden than ordinary Unocal review.5Justia Law. Blasius Industries Inc v Atlas Corp
Governance norms add another layer of constraint. Modern pills usually include a one-year sunset. Proxy advisory firm ISS generally recommends voting against board nominees at companies that keep a long-term pill in place without shareholder approval, and Glass Lewis takes a similar line. Features like “dead hand” provisions, which let only the original directors redeem the pill, and “slow hand” variants, which delay redemption after new directors take office, draw opposition from ISS and face severe judicial scrutiny because they undermine the shareholder franchise.
How Bidders Get Past a Pill
A poison pill is an obstacle, not a wall. Hostile bidders have several paths around it.
Board Redemption
The simplest path is to convince the board to redeem the rights voluntarily. Boards can cancel the rights for a nominal price, usually a few cents per right. This typically happens when the bidder raises its offer to a price the board considers fair. Redemption converts a hostile bid into a negotiated one, and that is often how these situations end. The pill does not block the deal; it forces a better price.
Qualifying Offer Clauses
Some pills include a “qualifying offer” provision that creates a contractual bypass. If the bidder’s offer meets specific criteria, usually a fully financed all-cash or all-shares offer held open for a minimum period, the pill either does not trigger or shareholders can vote to override the board’s refusal to redeem. Nearly 60% of institutional investors surveyed by ISS consider this feature important enough that it should be in every pill. The clause gives shareholders a safety valve against boards that might use the pill to entrench themselves.
The Proxy Contest
If the board will not redeem and no qualifying offer clause exists, the bidder’s remaining option is to replace the board itself. A proxy contest asks shareholders to elect new directors who will redeem the pill and approve the deal. It usually runs alongside the tender offer, creating a dual-track campaign.
This is where a classified, or staggered, board becomes decisive. If directors are elected in staggered classes, with roughly a third of the board up each year, a bidder cannot replace a majority in a single election. Two annual meeting cycles are required, which stretches a takeover fight over at least a year. The combination of a poison pill and a staggered board is the most formidable defense in corporate law. Delaware courts have held the combination is not inherently impermissible, provided the bidder has a realistic opportunity to wage a proxy contest.5Justia Law. Blasius Industries Inc v Atlas Corp
What a Pill Means for Shareholders
Whether pills help or hurt the shareholders they are issued to is genuinely contested, and honest people disagree.
The argument in favor is that pills prevent a bidder from acquiring the company on the cheap by forcing a negotiation. Target shareholders tend to receive higher premiums in negotiated deals than in uncontested tender offers, and the pill is the reason the negotiation happens. Without it, a bidder could accumulate shares in the open market, bypass the board, and pressure scattered shareholders into accepting a lowball price.
The argument against is that pills give boards the power to block deals that shareholders might actually want to accept. A board that says “this offer undervalues the company” might be right, or might be protecting its own jobs. Empirical research has found that the most restrictive pill defenses are associated with higher rates of defeated tender offers and modest negative effects on stock prices when adopted. The worry is that some boards use the pill as a bunker rather than a bargaining tool.
The practical resolution has been governance constraints rather than abolition. Short durations, shareholder ratification, qualifying offer clauses, independent director review, and proxy advisor oversight together limit the entrenchment risk without removing the leverage that makes pills useful at the bargaining table. A well-designed pill with a one-year term and a qualifying offer provision looks very different from a permanent pill with a dead hand feature, and courts, investors, and proxy advisors treat them accordingly.